Development of neonatal screening in Colombia: Tandem mass spectrometry
Main Article Content
Abstract
DOI: 10.1016/j.rcpe.2015.07.006
Background
In Colombia there are laws such as the rare diseases Law 1392 / 2010, and the children and adolescents Law 1098 / 2006, which protect the rights of children in the prevention of disability. A key strategy to achieve this is neonatal population screening.
Objectives
To describe the operational indicators of the neonatal screening program in Colombia for congenital hypothyroidism for the years 2009 to 2014, and to describe the beginning of extended screening by tandem mass spectrometry.
Methods
The information used was obtained from the program for evaluation of screening laboratories performance, the Sistema Nacional de Vigilancia, the Observatorio Nacional de Salud, and vital statistics of the Departmento Administrativo Nacional de Estadística, in order to review the operational indicators for the neonatal screening program in Colombia.
Results
Screening for congenital hypothyroidism has achieved a coverage rate of 80%, but is affected by the low rate of recall, which is less than 50%, leading to coverage being reduced by half, and which is reflected in the low incidence rates. The constraints in implementing an expanded screening program using tandem mass spectrometry are identified, as well as demonstrating the opportunity to identify serious diseases that affect infant mortality.
Conclusions
There is a need to review the current screening model, taking into account a new model based on centralisation and network nodes for the improvement of recall and coverage, as well as the implementation of expanded screening.
Downloads
Article Details
Creative Commons
License Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
You are free to:
Share - copy and redistribute the material in any medium or format.
Adapt - remix, transform, and build upon the material The licensor cannot revoke these freedoms as long as you follow the license terms.
• Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
• NonCommercial — You may not use the material for commercial purposes.
• ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
• No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
References
2 República de Colombia. Ministerio de la Protección Social. Decreto número 3518 de 2006, “Por el cual se crea y reglamenta el Sistema de Vigilancia en Salud Pública y se dictan otras disposiciones”.
3 República de Colombia. Ministerio de la Protección Social. Ley 1392 de 2010.
4 P.H. Arn
Newborn screening: current status
Health Aff (Millwood), 26 (2007), pp. 559-566
5 E.C. Neto,R. Rubin,J. Schulte,R. Giugliani
Newborn screening for congenital infectious diseases
Emerg Infect Dis., 10 (2004), pp. 1068-1073 http://dx.doi.org/10.3201/eid1006.030830
Medline
6 R.J. Pollitt
Neonatal screening
J Clin Pathol., 46 (1993), pp. 497-499
Medline
7 I. Sahai,D. Marsden
Newborn screening
Crit Rev Clin Lab Sci., 46 (2009), pp. 55-82 http://dx.doi.org/10.1080/10408360802485305
Medline
8 S.E. McCandless
A primer on expanded newborn screening by tandem mass spectrometry
Prim Care., 31 (2004), pp. 583-604 http://dx.doi.org/10.1016/j.pop.2004.04.004
Medline
9 G.J. Borrajo
Newborn screening in Latin America at the beginning of the 21st century
J Inherit Metab Dis., 30 (2007), pp. 466-481 http://dx.doi.org/10.1007/s10545-007-0669-9
Medline
10 Misnaza SP. Informe del evento hipotiroidismo congénito. Bogotá: Dirección de Vigilancia y Análisis del Riesgo en Salud Pública, Instituto Nacional de Salud; 2014.
11 International Standard. ISO-13528. Statistical methods for use in proficiency testing by interlaboratory comparisons. 1st ed. Geneva: The ISO Central SecretariatSwitzerland; 2005.
12 Queiruga G, Lemes A, Ferolla C, Machado M, Queijo C, Garlo P, et al. Pesquisa neonatal: lo que puede prevenir una gota de sangre. Primera edición. Montevideo: Centro de Estudios en Seguridad Social, Salud y Administración; 2010.
13 Nuñez RM. Carta al editor. Acta Pediatr Mex 2012; 33(3):158-161.
14 N. Rossato
Pesquisa neonatal obligatoria: reflexiones
Arch Argent Pediatr., 107 (2009), pp. 193-194 http://dx.doi.org/10.1590/S0325-00752009000300001
Medline
15 J.G. Dautt-Leyva
Tamiz neonatal, una herramienta epidemiológica
Arch Salud Sin., 6 (2012), pp. 20-22
16 D. Rosselli,J.D. Rueda,A. Ruiz
Análisis de costos de la tamización neonatal universal mediante espectrometría de masas en tándem para errores innatos del metabolismo en Colombia
Rev Pediatr., 47 (2014), pp. 31-38
17 California Department of Public Health. Genetic Disease Screening Program. May, 2013. Estimate for fiscal years 2012-13 and 2013-14 [consultado 30 Abr 2015]. Disponible en: http://www.cdph.ca.gov/pubsforms/fiscalrep/Documents/GDSP%20May%20Revise%20Estimate%202013-14%20FINAL.pdf.
18 Organización Mundial de la Salud. 63.ª Asamblea Mundial de la Salud. Documento A63/10. Punto 11.7 del orden del día. Ginebra: Organización Mundial de la Salud; 2010.
19 Instituto Nacional de Salud. Observatorio Nacional de Salud. Primer Informe ONS. Aspectos relacionados con la frecuencia de uso de los servicios de salud, mortalidad y discapacidad en Colombia, 2011. Bogotá: Imprenta Nacional de Colombia; 2013.
20 Cumbre de la ONU. Informe 2010 de objetivos de desarrollo del milenio. ONU-UNESCO. Nueva York: Naciones Unidas; 2010.
21 M. Vela-Amieva,L. Belmont-Martínez,I. Ibarra-González,C. Fernández-Laine
Variabilidad interinstitucional del tamiz neonatal en México
Bol Med Hosp Infant Mex., 66 (2009), pp. 431-439